Price Alert

Nuvation Bio Inc. (NUVB)

NYSE: NUVB · Real-Time Price · USD

3.88

0.46 (13.45%)

At close: Sep 05, 2025, 3:59 PM

3.93

1.15%

After-hours: Sep 05, 2025, 07:57 PM EDT

13.45% (1D)

Bid	3.87
Market Cap	1.33B
Revenue (ttm)	14.36M
Net Income (ttm)	-202.9M
EPS (ttm)	-0.41
PE Ratio (ttm)	-9.48
Forward PE	-6.1
Analyst	Buy

Ask	3.9
Volume	21,363,202
Avg. Volume (20D)	6,305,012
Open	3.48
Previous Close	3.42
Day's Range	3.47 - 4.09
52-Week Range	1.54 - 4.09
Beta	1.37

About NUVB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NUVB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NUVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Nuvation Bio Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

8 months ago

+14.44%

Nuvation Bio shares are trading higher after RBC C... Unlock content with Pro Subscription

News

1 week ago · seekingalpha.com

Nuvation Bio: What To Expect From IBTROZI Launch?

Nuvation Bio is a Buy after FDA approval of Ibtrozi, a highly selective ROS1+ NSCLC treatment with strong clinical results and brain metastasis efficacy. Ibtrozi demonstrated superior response rates a...

1 week ago · businesswire.com

Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Fou...

1 week ago · zacks.com

Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Nuvation Bio Inc. (NUVB) could be a good stock pick from a technical perspective. NUVB recently experienced a "golden cross" event, which saw its 50-day simp...

4 weeks ago · zacks.com

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.

4 weeks ago · businesswire.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quart...

1 month ago · businesswire.com

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

1 month ago · zacks.com

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy

Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.